Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could Moderna Justify Its $129 Billion Valuation?

TheMotleyFool

0 0

Could Moderna Justify Its $129 Billion Valuation?

To say that Moderna's (NASDAQ: MRNA) COVID-19 vaccine has been a success would be a massive understatement, but there's no scenario where it justifies the company's $129 billion valuation all by itself. In this Fool Live video clip, recorded on Oct. 4, Fool.com contributor Matt Frankel discusses why Moderna's true value could lie in its future product pipeline.

Source Fool.com

Like: 0

MRNA

Share